QCG
CPRX

Quadrant Capital Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Quadrant Capital Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80
Closed -$1.98K – 1524
2026
Q1 		$1.98K Hold
80
– – ﹤0.01% 2508
2025
Q4 		$1.87K Hold
80
– – ﹤0.01% 2533
2025
Q3 		$1.58K Buy
+80
New +$1.65K ﹤0.01% 2511
2025
Q2 		– Sell
-842
Closed -$20.4K – 1619
2025
Q1 		$20.4K Buy
+842
New +$19K ﹤0.01% 2025
2023
Q2 		– Sell
-81
Closed -$1.34K – 2705
2023
Q1 		$1.34K Buy
81
+16
+25% +$264 ﹤0.01% 2496
2022
Q4 		$1.21K Buy
+65
New +$1K ﹤0.01% 2508

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrant Capital Group's CPRX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 80 shares — an estimated $1.98K sold.

Quadrant Capital Group first reported a position in CPRX in Q4 2022 and held it in 6 quarters. The position peaked at $20.4K in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 80 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.98K.
  • Quadrant Capital Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 6 quarters.
  • Quadrant Capital Group's Catalyst Pharmaceutical position peaked at $20.4K in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.